Abbott Laboratories (ABT.N)
54.12USD
22 Dec 2009
$0.20 (+0.37%)
$53.92
$54.10
$54.29
$54.02
1,349,800
5,701,499
$57.39
$41.27
About
Overall
| Beta: | 0.19 |
| Market Cap (Mil.): | $83,400.13 |
| Shares Outstanding (Mil.): | 1,546.74 |
| Annual Dividend: | 1.60 |
| Yield (%): | 2.97 |
Financials
| ABT.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 14.99 | 3.57 | 4.64 |
| EPS (TTM): | 23.36 | -- | -- |
| ROI: | 16.11 | 1.79 | 2.82 |
| ROE: | 27.52 | 2.40 | 3.58 |
'Good' cholesterol less protective with diabetes
CHICAGO, Dec 22 (Reuters) - Diabetes may lower the heart-protective benefits of high-density lipoprotein, or HDL, the so-called "good" cholesterol, but giving diabetics niacin, a drug that raises HDL levels, might restore the benefit, researchers said on Tuesday.
UPDATE 3-US FDA: unlikely Merck's Vytorin ups cancer risk
* No cancer risk seen in early results of 2 large studies
EU mergers and takeovers (Dec 21)
BRUSSELS, Dec 21 (Reuters) - The following are planned mergers under review by the European Commission and a brief guide to the EU merger process:
CORRECTED - UPDATE 1-Celgene psoriasis drug shows promise in trial
(Corrects ninth paragraph of Dec. 15 story to show Stelara targets interleukin proteins, not TNF)
UPDATE 2-US warns Abbott unit on problems at Swedish plant
* Cites issues at Advanced Medical Optics plant in Sweden
UPDATE 1-Celgene psoriasis drug shows promise in trial
* J.P. Morgan analyst sees potential sales of $500 million
US STOCKS-Futures slip on strong dollar; data on tap
* Futures lower: S&P 3.3 pts, Dow 20 pts, Nasdaq 5.5 pts
US STOCKS-Futures slip after gains, data on tap
* Futures lower: S&P by 3 pts, Dow 29 pts, Nasdaq 5.25 pts
U.S. stock futures signal weaker open; data eyed
* Futures for the Dow Jones industrial average , the S&P 500 and the Nasdaq 100 were down 0.2 to 0.3 percent at 1006 GMT, pointing to a weaker start on Wall Street on Tuesday.
AFTER THE BELL-Abbott Labs to buy Starlims; shares surge
NEW YORK, Dec 14 (Reuters) - Starlims Technologies Ltd shares surged 41.6 percent in extended trade on Monday after the company agreed to be acquired by Abbott Laboratories for about $123 million. [ID:nWNBB1098] (Reporting by Chuck Mikolajczak; Editing by Dan Grebler)
Competitors
| Price | Change | |
|---|---|---|
| Johnson & Johnson (JNJ.N) | $64.53 | +0.20 |
| Pfizer Inc. (PFE.N) | $18.61 | 0.00 |
| GlaxoSmithKline plc (GSK.L) | £1,326.00 | +25.00 |
| Novartis AG (NOVN.VX) | CHF56.85 | +0.60 |
| Bayer AG (BAYGn.DE) | €55.43 | -0.29 |
| Bayer AG (BAYE.F) | -- | -- |
| AstraZeneca plc (AZN.L) | £2,889.00 | +52.00 |
| Eli Lilly & Co. (LLY.N) | $36.11 | -0.13 |
| Wyeth (WYE.N) | -- | -- |
| Wyeth (WYE_p.N) | -- | -- |





Earnings vs
Estimates